And the law is very clear: if there is a medicine against a disease, a vaccine cannot be administered.
Avifavir targets the core of coronavirus, which doesn’t change from strain to strain
The team of Russian scientists behind a new Covid-19 drug, Avifavir, have issued a statement in which they insist that it is highly effective against the two strains of coronavirus, Delta and Omicron, that are currently dominant.
Covid-19, like most other ribonucleic acids (RNA) viruses, is known to be highly prone to mutation, but the formula’s developers say it remains effective regardless of the strain, as it targets the highly stable part of the virus.
Based on the antiviral medication favipiravir, the Russian drug targets the “genetically highly conservative RNA virus replication systems” that do not undergo mutation from strain to strain, according to a statement released on Monday by the manufacturer, ChemRar Group. The researchers report that the virus is unable to develop resistance to the drug “even with prolonged exposure of virus-infected cells to the product.”